UCN-01 (cas 112953-11-4) in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium
-
Add time:08/03/2019 Source:sciencedirect.com
Background and objectiveUCN-01 (cas 112953-11-4) is a staurosporine analogue shown to abrogate the G2 checkpoint through inhibition of cyclin-dependent kinases. Preclinical evidence suggests synergy between UCN-01 and cytotoxic chemotherapy. Topotecan is an active agent in ovarian cancer. This phase II study was conducted to investigate the safety and efficacy of topotecan and UCN-01 in patients with advanced ovarian cancer.
We also recommend Trading Suppliers and Manufacturers of UCN-01 (cas 112953-11-4). Pls Click Website Link as below: cas 112953-11-4 suppliers
Prev:Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01 (cas 112953-11-4), in human plasma or urine
Next:Controlled release of a protein kinase inhibitor UCN-01 (cas 112953-11-4) from liposomes influenced by the particle size) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- UCN-01 (cas 112953-11-4), an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily08/05/2019
- Controlled release of a protein kinase inhibitor UCN-01 (cas 112953-11-4) from liposomes influenced by the particle size08/04/2019
- Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01 (cas 112953-11-4), in human plasma or urine08/02/2019
- AG490 influences UCN-01 (cas 112953-11-4)-induced cytotoxicity in Glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation08/01/2019
- Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 (cas 112953-11-4) in human plasma07/31/2019
- MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 (cas 112953-11-4) by exacerbating radiation-induced aberrant mitosis07/30/2019
- The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01 (cas 112953-11-4), induces fragmentation: Possible role of metalloproteinases07/29/2019
- Celecoxib Enhances the Radiosensitizing Effect of 7-Hydroxystaurosporine (UCN-01 (cas 112953-11-4)) in Human Lung Cancer Cell Lines07/28/2019
- The combination of UCN-01 (cas 112953-11-4) and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK07/27/2019